Loading...
Recent guidelines from the American Diabetes Association (ADA) recommend expanded use of continuous glucose monitors (CGMs) in patients with type 2 diabetes. However, the real-world benefits of CGM use in this population remain uncertain.
In this open-label, industry-supported trial, researchers recruited 300 patients with type 2 diabetes (mean age, 61; mean diabetes duration, 17 years) from the U.K. At baseline, participants were taking basal insulin plus various other antidiabetes drugs, including sodium–glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and metformin. Patients were randomized to CGM use or self-monitoring of blood glucose in two phases: A self-management phase (weeks 1–16) that involved …